Skip to main content
Erschienen in: Journal of Clinical Immunology 5/2008

01.09.2008

IkBα Promoter Polymorphisms in Patients with Primary Sjögren’s Syndrome

verfasst von: Tsan-Teng Ou, Chia-Hui Lin, Yu-Chih Lin, Ruei-Nian Li, Wen-Chan Tsai, Hong-Wen Liu, Jeng-Hsien Yen

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To investigate the association of IkBα promoter polymorphisms with the development of primary Sjögren’s syndrome in Taiwan, 98 patients with primary Sjögren’s syndrome and 110 unrelated healthy controls were enrolled in this study.

Materials and Methods

The IκBα −881 A/G, IκBα −826 C/T, IκBα −550 A/T, IκBα −519 C/T, and IκBα −297 C/T polymorphisms were determined by the methods of polymerase chain reaction/restriction fragment length polymorphism.

Results

This study demonstrated that the genotype frequencies of IκBα −826 C/T and IκBα −826 T/T, in comparison with that of IκBα −826 C/C, were significantly higher in the patients with primary Sjögren’s syndrome than in the controls. The allele frequency of IκBα −881 G was significantly decreased in the patients with primary Sjögren’s syndrome compared with that of the controls. In contrast, the allele frequency of IκBα −826 T was significantly higher in the patients with primary Sjögren’s syndrome than in the controls. The similar findings could also be found in the allele carriage frequencies. The patients with primary Sjögren’s syndrome had lower allele carriage frequencies of IκBα −881 G and IκBα −826 C, and a higher allele carriage frequency of IκBα −826 T. We also found that the estimated haplotype frequency of IκBα −881A-826T-550A-519C-297C was significantly increased in the patients with primary Sjögren’s syndrome in comparison with that of the controls.

Discussion

This study demonstrated that the IkBα −826T allele and IkBα −881A-826T-550A-519C-297C haplotype were associated with susceptibility to primary Sjögren’s syndrome in Taiwan. However, these findings may not be disease-specific but may be related to inflammatory responses.
Literatur
1.
Zurück zum Zitat Fox PC. Autoimmune diseases and Sjogren’s syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007;1098:15–21.PubMedCrossRef Fox PC. Autoimmune diseases and Sjogren’s syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007;1098:15–21.PubMedCrossRef
2.
Zurück zum Zitat Bolstad AI, Jonsson R. Genetic aspects of Sjogren’s syndrome. Arthritis Res 2002;4(6):353–9.PubMedCrossRef Bolstad AI, Jonsson R. Genetic aspects of Sjogren’s syndrome. Arthritis Res 2002;4(6):353–9.PubMedCrossRef
3.
Zurück zum Zitat Anaya JM, Mantilla RD, Correa PA. Immunogenetics of primary Sjogren’s syndrome in Colombians. Semin Arthritis Rheum 2005;34(5):735–43.PubMedCrossRef Anaya JM, Mantilla RD, Correa PA. Immunogenetics of primary Sjogren’s syndrome in Colombians. Semin Arthritis Rheum 2005;34(5):735–43.PubMedCrossRef
4.
Zurück zum Zitat Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjogren’s syndrome salivary glands. Lab Invest 1997;77(3):269–80.PubMed Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjogren’s syndrome salivary glands. Lab Invest 1997;77(3):269–80.PubMed
5.
Zurück zum Zitat Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336(15):1066–71.PubMedCrossRef Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336(15):1066–71.PubMedCrossRef
6.
Zurück zum Zitat Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998;8(1):R19–22.PubMedCrossRef Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998;8(1):R19–22.PubMedCrossRef
7.
Zurück zum Zitat Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107(1):7–11.PubMedCrossRef Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107(1):7–11.PubMedCrossRef
8.
Zurück zum Zitat Castro-Alcaraz S, Miskolci V, Kalasapudi B, Davidson D, Vancurova I. NF-kappa B regulation in human neutrophils by nuclear I kappa B alpha: correlation to apoptosis. J Immunol 2002;169(7):3947–53.PubMed Castro-Alcaraz S, Miskolci V, Kalasapudi B, Davidson D, Vancurova I. NF-kappa B regulation in human neutrophils by nuclear I kappa B alpha: correlation to apoptosis. J Immunol 2002;169(7):3947–53.PubMed
9.
Zurück zum Zitat Dale E, Davis M, Faustman DL. A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ 2006;30(4):152–8.PubMedCrossRef Dale E, Davis M, Faustman DL. A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ 2006;30(4):152–8.PubMedCrossRef
10.
Zurück zum Zitat Kawakami A, Eguchi K. Involvement of apoptotic cell death in autoimmune diseases. Med Electron Microsc 2002;35(1):1–8.PubMedCrossRef Kawakami A, Eguchi K. Involvement of apoptotic cell death in autoimmune diseases. Med Electron Microsc 2002;35(1):1–8.PubMedCrossRef
11.
Zurück zum Zitat Mozzato-Chamay N, Corbett EL, Bailey RL, Mabey DC, Raynes J, Conway DJ. Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun 2001;2(3):153–5.PubMedCrossRef Mozzato-Chamay N, Corbett EL, Bailey RL, Mabey DC, Raynes J, Conway DJ. Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun 2001;2(3):153–5.PubMedCrossRef
12.
Zurück zum Zitat Ito CY, Kazantsev AG, Baldwin AS Jr. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res 1994;22(18):3787–92.PubMedCrossRef Ito CY, Kazantsev AG, Baldwin AS Jr. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res 1994;22(18):3787–92.PubMedCrossRef
13.
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002;61(6):554–8.PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002;61(6):554–8.PubMedCrossRef
14.
Zurück zum Zitat Lin CH, Wang SC, Ou TT, Li RN, Tsai WC, Liu HW, et al. IkappaBalpha promoter polymorphisms in patients with systemic lupus erythematosus. J Clin Immunol 2007;11:11. Lin CH, Wang SC, Ou TT, Li RN, Tsai WC, Liu HW, et al. IkappaBalpha promoter polymorphisms in patients with systemic lupus erythematosus. J Clin Immunol 2007;11:11.
15.
Zurück zum Zitat May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 1997;8(2):63–73.PubMedCrossRef May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 1997;8(2):63–73.PubMedCrossRef
16.
Zurück zum Zitat Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 1995;15(5):2689–96.PubMed Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 1995;15(5):2689–96.PubMed
17.
Zurück zum Zitat Turpin P, Hay RT, Dargemont C. Characterization of IkappaBalpha nuclear import pathway. J Biol Chem 1999;274(10):6804–12.PubMedCrossRef Turpin P, Hay RT, Dargemont C. Characterization of IkappaBalpha nuclear import pathway. J Biol Chem 1999;274(10):6804–12.PubMedCrossRef
18.
Zurück zum Zitat Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997;110(Pt 3):369–78.PubMed Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997;110(Pt 3):369–78.PubMed
19.
Zurück zum Zitat Ernst MK, Dunn LL, Rice NR. The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers. Mol Cell Biol 1995;15(2):872–82.PubMed Ernst MK, Dunn LL, Rice NR. The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers. Mol Cell Biol 1995;15(2):872–82.PubMed
20.
Zurück zum Zitat Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigk S, et al. Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 2002;3(4):211–9.PubMedCrossRef Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigk S, et al. Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 2002;3(4):211–9.PubMedCrossRef
21.
Zurück zum Zitat Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen JT, et al. A polymorphism of the NFKBIA gene is associated with Crohn’s disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis 2004;19(2):153–6.PubMedCrossRef Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen JT, et al. A polymorphism of the NFKBIA gene is associated with Crohn’s disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis 2004;19(2):153–6.PubMedCrossRef
22.
Zurück zum Zitat Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH. IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis. Int J Immunogenet 2007;34(1):51–4.PubMedCrossRef Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH. IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis. Int J Immunogenet 2007;34(1):51–4.PubMedCrossRef
Metadaten
Titel
IkBα Promoter Polymorphisms in Patients with Primary Sjögren’s Syndrome
verfasst von
Tsan-Teng Ou
Chia-Hui Lin
Yu-Chih Lin
Ruei-Nian Li
Wen-Chan Tsai
Hong-Wen Liu
Jeng-Hsien Yen
Publikationsdatum
01.09.2008
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 5/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9212-5

Weitere Artikel der Ausgabe 5/2008

Journal of Clinical Immunology 5/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.